Antidote Technologies, developer of a recruitment platform for clinical trials, has agreed an $11m round that will be led by Merck Global Health Innovation Fund.
Merck Global Health Innovation Fund (GHI), a subsidiary of US-based pharmaceutical firm Merck & Co, agreed on Friday to lead an $11m funding round for UK-based clinical testing access developer Antidote Technologies.
Venture capital firm Smedvig Capital and Octopus Ventures, which forms part of fund manager Octopus Group, are also participating in the round, which will increase Antidote’s total funding to $26m once regulatory clearance has been secured.
Antidote has created a clinical trial matching platform called Antidote Match that…
